董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David A. Ricks | 男 | Chair, President and Chief Executive Officer | 56 | 2139.81万美元 | 68.72 | 2024-02-21 |
| Gabrielle Sulzberger | 女 | Director | 64 | 28.63万美元 | 未持股 | 2024-02-21 |
| Karen Walker | 女 | Director | 62 | 33.40万美元 | 未持股 | 2024-02-21 |
| Kimberly H. Johnson | -- | Director | 51 | 26.16万美元 | 未持股 | 2024-02-21 |
| Erik Fyrwald | -- | Director | -- | 未披露 | 未持股 | 2024-02-21 |
| Mary Lynne Hedley | -- | Director | -- | 未披露 | 0.03 | 2024-02-21 |
| Ralph Alvarez | 男 | Director | 68 | 30.60万美元 | 未持股 | 2024-02-21 |
| Juan R. Luciano | 男 | Director | 62 | 32.60万美元 | 未持股 | 2024-02-21 |
| Katherine Baicker | 女 | Director | 52 | 30.60万美元 | 未持股 | 2024-02-21 |
| William G. Kaelin, Jr. | 男 | Director | 66 | 31.60万美元 | 未持股 | 2024-02-21 |
| Marschall S. Runge | 男 | Director | 69 | 29.40万美元 | 0.02 | 2024-02-21 |
| Jamere Jackson | 男 | Director | 55 | 31.20万美元 | 未持股 | 2024-02-21 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David A. Ricks | 男 | Chair, President and Chief Executive Officer | 56 | 2139.81万美元 | 68.72 | 2024-02-21 |
| Jacob Van Naarden | 男 | Executive Vice President and President | 39 | 612.27万美元 | 2.05 | 2024-02-21 |
| Johna L. Norton | 女 | Executive Vice President, Global Quality | 57 | 未披露 | 未持股 | 2024-02-21 |
| Daniel Skovronsky | 男 | Executive Vice President, Chief Scientific Officer and President | 50 | 846.38万美元 | 19.37 | 2024-02-21 |
| Anne E. White | 女 | Executive Vice President and President, Lilly Neuroscience | 55 | 未披露 | 未持股 | 2024-02-21 |
| Donald A. Zakrowski | -- | Senior Vice President, Finance and Chief Accounting Officer | -- | 未披露 | 未持股 | 2024-02-21 |
| Anat Hakim | 女 | Executive Vice President, General Counsel and Secretary | 54 | 543.19万美元 | 3.05 | 2024-02-21 |
| Patrik Jonsson | 男 | Executive Vice President and President, Lilly Diabetes and Obesity and President | 57 | 392.33万美元 | 未持股 | 2024-02-21 |
| Anat Ashkenazi | 女 | Executive Vice President and Chief Financial Officer | 52 | 526.03万美元 | 4.25 | 2024-02-21 |
| Ilya Yuffa | 男 | Executive Vice President and President, Lilly International | 49 | 未披露 | 未持股 | 2024-02-21 |
| Edgardo Hernandez | 男 | Executive Vice President and President, Manufacturing Operations | 49 | 未披露 | 未持股 | 2024-02-21 |
| Diogo Rau | 男 | Executive Vice President and Chief Information and Digital Officer | 49 | 510.13万美元 | 未持股 | 2024-02-21 |
| Alonzo Weems | 男 | Executive Vice President, Enterprise Risk Management and Chief Ethics and Compliance Officer | 53 | 未披露 | 未持股 | 2024-02-21 |
| Eric Dozier | 男 | Executive Vice President, Human Resources and Diversity | 57 | 未披露 | 未持股 | 2024-02-21 |
董事简历
中英对照 | 中文 | 英文- David A. Ricks
-
David A. Ricks，他是礼来生物药品公司的高级副总裁及总裁（自2012年1月）。
David A. Ricks,held various leadership roles with Lilly, including senior vice president and president, Lilly Bio-Medicines. Mr. Ricks has 27 years of service with Lilly. - David A. Ricks，他是礼来生物药品公司的高级副总裁及总裁（自2012年1月）。
- David A. Ricks,held various leadership roles with Lilly, including senior vice president and president, Lilly Bio-Medicines. Mr. Ricks has 27 years of service with Lilly.
- Gabrielle Sulzberger
-
Gabrielle Sulzberger自2003年起担任公司的董事。Sulzberger女士担任一个多元化投资基金，Rustic Canyon/Fontis Partners, LP的负责人（2005年10月公司成立起担任此职位）。另外，Sulzberger女士担任Villanueva公司（Villanueva Companies，一家私人持股公司，拥有多元化的投资利益）担任财务总监（2002-2005年）。Sulzberger女士也在Stage Stores股份有限公司（Stage Stores, Inc.）和Brixmor Property Group股份有限公司（Brixmor Property Group Inc.）董事会工作。
Gabrielle Sulzberger,Senior Advisor, Two Sigma Impact, a private equity fund (since August 2020);General Partner, Fontis Partners, L.P. (2005-2018);CFO, Gluecode Software Inc. (open-source software company);CFO, Crown Services (commercial contractors). - Gabrielle Sulzberger自2003年起担任公司的董事。Sulzberger女士担任一个多元化投资基金，Rustic Canyon/Fontis Partners, LP的负责人（2005年10月公司成立起担任此职位）。另外，Sulzberger女士担任Villanueva公司（Villanueva Companies，一家私人持股公司，拥有多元化的投资利益）担任财务总监（2002-2005年）。Sulzberger女士也在Stage Stores股份有限公司（Stage Stores, Inc.）和Brixmor Property Group股份有限公司（Brixmor Property Group Inc.）董事会工作。
- Gabrielle Sulzberger,Senior Advisor, Two Sigma Impact, a private equity fund (since August 2020);General Partner, Fontis Partners, L.P. (2005-2018);CFO, Gluecode Software Inc. (open-source software company);CFO, Crown Services (commercial contractors).
- Karen Walker
-
Karen Walker，她于2008年11月加入Cisco公司，并担任副总裁，负责服务营销（从2008年11月到2012年1月）。从2012年2月到2013年1月，她曾担任高级副总裁，负责部门、服务、合伙人营销。从2013年2月到2015年5月，她曾担任高级副总裁，负责上市。她于2015年5月被提升为公司的现任职务。加入Cisco公司之前，她曾任职Hewlett-Packard公司，在那里她曾担任商业和消费者领导职务，包括消费者数字娱乐和个人系统集团的负责人力资源服务的合规和营销副总裁，以及战略营销副总裁。
Karen Walker,Operating Partner, The Goldman Sachs Group, Inc.. - Karen Walker，她于2008年11月加入Cisco公司，并担任副总裁，负责服务营销（从2008年11月到2012年1月）。从2012年2月到2013年1月，她曾担任高级副总裁，负责部门、服务、合伙人营销。从2013年2月到2015年5月，她曾担任高级副总裁，负责上市。她于2015年5月被提升为公司的现任职务。加入Cisco公司之前，她曾任职Hewlett-Packard公司，在那里她曾担任商业和消费者领导职务，包括消费者数字娱乐和个人系统集团的负责人力资源服务的合规和营销副总裁，以及战略营销副总裁。
- Karen Walker,Operating Partner, The Goldman Sachs Group, Inc..
- Kimberly H. Johnson
-
Kimberly H. Johnson，2018年到至今担任联邦国民抵押贷款协会Fannie Mae，美国可负担抵押贷款融资提供公司的执行副总裁兼首席运营官，执行副总裁兼首席风险官（2017-2018年），高级副总裁兼首席风险官（2015-2017年），高级副总裁兼副首席风险官（2013-2015年）。Credit Suisse AG，一家成立于瑞士的全球财富管理、投资银行和金融服务公司，利率衍生产品总监（2005-2006年），副总裁（2002-2004年）。
Kimberly H. Johnson Federal National Mortgage Association Fannie Mae, provider of affordable mortgage financing in the United States Executive Vice President and Chief Operating Officer (2018 - present),Executive Vice President and Chief Risk Officer (2017 - 2018),Senior Vice President and Chief Risk Officer (2015 - 2017),Senior Vice President and Deputy Chief Risk Officer (2013 - 2015).Credit Suisse AG, a global wealth manager, investment bank, and financial services firm founded and based in Switzerland,Director, Interest Rate Derivative Products (2005 - 2006),Vice President (2002 - 2004). - Kimberly H. Johnson，2018年到至今担任联邦国民抵押贷款协会Fannie Mae，美国可负担抵押贷款融资提供公司的执行副总裁兼首席运营官，执行副总裁兼首席风险官（2017-2018年），高级副总裁兼首席风险官（2015-2017年），高级副总裁兼副首席风险官（2013-2015年）。Credit Suisse AG，一家成立于瑞士的全球财富管理、投资银行和金融服务公司，利率衍生产品总监（2005-2006年），副总裁（2002-2004年）。
- Kimberly H. Johnson Federal National Mortgage Association Fannie Mae, provider of affordable mortgage financing in the United States Executive Vice President and Chief Operating Officer (2018 - present),Executive Vice President and Chief Risk Officer (2017 - 2018),Senior Vice President and Chief Risk Officer (2015 - 2017),Senior Vice President and Deputy Chief Risk Officer (2013 - 2015).Credit Suisse AG, a global wealth manager, investment bank, and financial services firm founded and based in Switzerland,Director, Interest Rate Derivative Products (2005 - 2006),Vice President (2002 - 2004).
- Erik Fyrwald
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Mary Lynne Hedley
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Ralph Alvarez
-
Ralph Alvarez于2013年至今在加州风洋食馆担任执行董事长职务。加州风洋食馆是一家主要在日本经营的餐馆运营公司。自2006年至2009年期间内，他在麦当劳连锁速食店担任总裁兼首席运营官。他还在以下公司和组织任职：迈阿密大学、总裁委员会、工商管理学院董事会监督部和国际顾问委员会。他也在以下公共公司董事会任职：劳氏公司、敦肯布兰德集团、Realogy控股公司。他也在加州风洋食馆董事会任职，加州风洋食馆是一家私人公司。在此之前，他在麦当劳连锁速食店和科凯国际集团董事会任职。
Ralph Alvarez Advent International Corporation, a leading global private equity firm Operating Partner 2017 - present.Skylark Co., Ltd., a leading restaurant operator in Japan Chairman of the Board (2013 - 2018).McDonald's Corporation, a leading global foodservice retailer President and Chief Operating Officer (2006 - 2009). - Ralph Alvarez于2013年至今在加州风洋食馆担任执行董事长职务。加州风洋食馆是一家主要在日本经营的餐馆运营公司。自2006年至2009年期间内，他在麦当劳连锁速食店担任总裁兼首席运营官。他还在以下公司和组织任职：迈阿密大学、总裁委员会、工商管理学院董事会监督部和国际顾问委员会。他也在以下公共公司董事会任职：劳氏公司、敦肯布兰德集团、Realogy控股公司。他也在加州风洋食馆董事会任职，加州风洋食馆是一家私人公司。在此之前，他在麦当劳连锁速食店和科凯国际集团董事会任职。
- Ralph Alvarez Advent International Corporation, a leading global private equity firm Operating Partner 2017 - present.Skylark Co., Ltd., a leading restaurant operator in Japan Chairman of the Board (2013 - 2018).McDonald's Corporation, a leading global foodservice retailer President and Chief Operating Officer (2006 - 2009).
- Juan R. Luciano
-
Juan R. Luciano，自2014年2月以来，担任总裁兼首席运营官。2011年4月至2014年2月，担任执行副总裁兼首席运营官。2010年8月至2011年4月，担任陶氏化学公司性能部门的执行副总裁。2008年12月至2010年8月，担任套是化学公司碳氢化合物和基本塑料事业部的高级副总裁。
Juan R. Luciano,Since joining ADM in 2011, Mr. Luciano has spent more than a decade in various senior executive leadership roles working to drive Archer-Daniels-Midland Company Company's evolution. During his time with ADM he has spearheaded Archer-Daniels-Midland Company major growth drivers and sales and marketing efforts, including the commercial and production activities of ADM's corn, oilseeds, and agricultural services businesses, development of sustainability strategy, and the increased Archer-Daniels-Midland Company e of research and technological innovation to meet customer needs. He most recently led a strategic growth campaign that has expanded ADM's footprint in global markets, including through select M&A activity, building capabilities and adding talent and expertise that have allowed Archer-Daniels-Midland Company Company to create value at every part of the global value chain. Under his leadership, ADM has undergone a remarkable transformation, building on more than a century of heritage to create a global nutrition business, with an industry-leading array of ingredients and solutions that are opening the door to growth opportunities in key global macro trend areas. He also has overseen the Company's operational excellence initiatives and risk management functions. Prior to joining ADM, he had a successful 25-year tenure at The Dow Chemical Company, where he last served as executive vice president and president of the Performance division. - Juan R. Luciano，自2014年2月以来，担任总裁兼首席运营官。2011年4月至2014年2月，担任执行副总裁兼首席运营官。2010年8月至2011年4月，担任陶氏化学公司性能部门的执行副总裁。2008年12月至2010年8月，担任套是化学公司碳氢化合物和基本塑料事业部的高级副总裁。
- Juan R. Luciano,Since joining ADM in 2011, Mr. Luciano has spent more than a decade in various senior executive leadership roles working to drive Archer-Daniels-Midland Company Company's evolution. During his time with ADM he has spearheaded Archer-Daniels-Midland Company major growth drivers and sales and marketing efforts, including the commercial and production activities of ADM's corn, oilseeds, and agricultural services businesses, development of sustainability strategy, and the increased Archer-Daniels-Midland Company e of research and technological innovation to meet customer needs. He most recently led a strategic growth campaign that has expanded ADM's footprint in global markets, including through select M&A activity, building capabilities and adding talent and expertise that have allowed Archer-Daniels-Midland Company Company to create value at every part of the global value chain. Under his leadership, ADM has undergone a remarkable transformation, building on more than a century of heritage to create a global nutrition business, with an industry-leading array of ingredients and solutions that are opening the door to growth opportunities in key global macro trend areas. He also has overseen the Company's operational excellence initiatives and risk management functions. Prior to joining ADM, he had a successful 25-year tenure at The Dow Chemical Company, where he last served as executive vice president and president of the Performance division.
- Katherine Baicker
-
Katherine Baicker ，Harris 公共政策学院，芝加哥大学院长和 Emmett Dedmon 教授 2017 年至今。Harvard T.H. Chan 公共卫生学院，卫生政策与管理系 C. Boyden Gray 教授 （2014 - 2017） 代理主席 （2014 - 2016） 卫生经济学教授 （2007 - 2017）。总裁办公厅经济顾问委员会成员 （2005 - 2007） 高级经济学家 （2001 - 2002）。
Katherine Baicker ,Harris School of Public Policy, University of Chicago Dean and the Emmett Dedmon Professor 2017 - present.Harvard T.H. Chan School of Public Health, Department of Health Policy and Management C. Boyden Gray Professor (2014 - 2017) Acting Chair (2014 - 2016) Professor of health economics (2007 - 2017).Council of Economic Advisers, Executive Office of the President Member (2005 - 2007) Senior Economist (2001 - 2002). - Katherine Baicker ，Harris 公共政策学院，芝加哥大学院长和 Emmett Dedmon 教授 2017 年至今。Harvard T.H. Chan 公共卫生学院，卫生政策与管理系 C. Boyden Gray 教授 （2014 - 2017） 代理主席 （2014 - 2016） 卫生经济学教授 （2007 - 2017）。总裁办公厅经济顾问委员会成员 （2005 - 2007） 高级经济学家 （2001 - 2002）。
- Katherine Baicker ,Harris School of Public Policy, University of Chicago Dean and the Emmett Dedmon Professor 2017 - present.Harvard T.H. Chan School of Public Health, Department of Health Policy and Management C. Boyden Gray Professor (2014 - 2017) Acting Chair (2014 - 2016) Professor of health economics (2007 - 2017).Council of Economic Advisers, Executive Office of the President Member (2005 - 2007) Senior Economist (2001 - 2002).
- William G. Kaelin, Jr.
-
William G. Kaelin, Jr.于2002年至今在达纳—法勃尔/哈佛大学癌症中心担任医药学教授。自2009年至今他在基础科学部门担任副主任。他还在以下公司任职：美国医学研究所、美国国家科学院和美国医师协会。他获得了加拿大Gairdner国际奖项及法国研究所Lefoulon-Delalande奖。
William G. Kaelin, Jr.,Sidney Farber professor of Medicine, Harvard Medical School; Professor, Dana-Farber Cancer Institute and Brigham and Women's Hospital; Investigator, Howard Hughes Medical Institute. - William G. Kaelin, Jr.于2002年至今在达纳—法勃尔/哈佛大学癌症中心担任医药学教授。自2009年至今他在基础科学部门担任副主任。他还在以下公司任职：美国医学研究所、美国国家科学院和美国医师协会。他获得了加拿大Gairdner国际奖项及法国研究所Lefoulon-Delalande奖。
- William G. Kaelin, Jr.,Sidney Farber professor of Medicine, Harvard Medical School; Professor, Dana-Farber Cancer Institute and Brigham and Women's Hospital; Investigator, Howard Hughes Medical Institute.
- Marschall S. Runge
-
Marschall S. Runge于2010年至今在北卡罗来纳大学医学院担任执行校长。自2000年至今在医药部担任董事。他在北卡罗来纳州移植临床科学研究所担任首席研究员兼主任。他还在心血管科学实验研究部分的国家卫生研究院董事会担任董事。
Marschall S. Runge,CEO, Michigan Medicine, Executive Vice President for Medical Affairs and Dean, Medical School, University of Michigan. - Marschall S. Runge于2010年至今在北卡罗来纳大学医学院担任执行校长。自2000年至今在医药部担任董事。他在北卡罗来纳州移植临床科学研究所担任首席研究员兼主任。他还在心血管科学实验研究部分的国家卫生研究院董事会担任董事。
- Marschall S. Runge,CEO, Michigan Medicine, Executive Vice President for Medical Affairs and Dean, Medical School, University of Michigan.
- Jamere Jackson
-
Jamere Jackson于2020年9月13日被任命为执行副总裁兼首席财务官，自2021年1月1日起担任财务与商店发展首席财务官兼执行副总裁。自2018年以来，杰克逊先生一直担任全球租赁公司Hertz Global Holdings，Inc.的执行副总裁兼首席财务官。HertzGlobal Holdings，Inc.于2020年5月22日申请第11章破产。从2014年至2018年，Jackson先生曾担任信息，数据和度量公司Nielsen Holdings plc的首席财务官。在2014年之前，Jackson先生在通用电气公司（General Electric Company）担任过各种领导职务，包括通用电气石油和天然气部门的副总裁兼首席财务官。Jackson先生现任礼来公司（Eli Lilly＆Co.）和希贝特体育（Hibbett Sports，Inc.）的董事会成员。
Jamere Jackson,joined AutoZone on September 13, 2020 as Executive Vice President and Chief Financial Officer. Prior to joining AutoZone, from 2018 to 2020, he served as Executive Vice President and Chief Financial Officer of Hertz Global Holdings, Inc., a worldwide rental company. From 2014 to 2018, he served as Chief Financial Officer of Nielsen Holdings plc, an information, data and measurement company. Prior to 2014, he held a variety of leadership roles at General Electric Company. Mr. Jackson serves on the Board of Directors for Eli Lilly & Co. - Jamere Jackson于2020年9月13日被任命为执行副总裁兼首席财务官，自2021年1月1日起担任财务与商店发展首席财务官兼执行副总裁。自2018年以来，杰克逊先生一直担任全球租赁公司Hertz Global Holdings，Inc.的执行副总裁兼首席财务官。HertzGlobal Holdings，Inc.于2020年5月22日申请第11章破产。从2014年至2018年，Jackson先生曾担任信息，数据和度量公司Nielsen Holdings plc的首席财务官。在2014年之前，Jackson先生在通用电气公司（General Electric Company）担任过各种领导职务，包括通用电气石油和天然气部门的副总裁兼首席财务官。Jackson先生现任礼来公司（Eli Lilly＆Co.）和希贝特体育（Hibbett Sports，Inc.）的董事会成员。
- Jamere Jackson,joined AutoZone on September 13, 2020 as Executive Vice President and Chief Financial Officer. Prior to joining AutoZone, from 2018 to 2020, he served as Executive Vice President and Chief Financial Officer of Hertz Global Holdings, Inc., a worldwide rental company. From 2014 to 2018, he served as Chief Financial Officer of Nielsen Holdings plc, an information, data and measurement company. Prior to 2014, he held a variety of leadership roles at General Electric Company. Mr. Jackson serves on the Board of Directors for Eli Lilly & Co.
高管简历
中英对照 | 中文 | 英文- David A. Ricks
David A. Ricks，他是礼来生物药品公司的高级副总裁及总裁（自2012年1月）。
David A. Ricks,held various leadership roles with Lilly, including senior vice president and president, Lilly Bio-Medicines. Mr. Ricks has 27 years of service with Lilly.- David A. Ricks，他是礼来生物药品公司的高级副总裁及总裁（自2012年1月）。
- David A. Ricks,held various leadership roles with Lilly, including senior vice president and president, Lilly Bio-Medicines. Mr. Ricks has 27 years of service with Lilly.
- Jacob Van Naarden
Jacob Van Naarden，自2015年12月起担任Loxo Oncology, Inc.首席商务官，自2014年5月担任Loxo Oncology, Inc.开发战略部副总裁。加入Loxo Oncology前，2013年7月至2014年5月，Mr. Van Naarden曾担任HealthCor Management分析师。2008年8月至2013年6月，Mr. Van Naarden曾在Aisling Capital任职，一开始担任分析师后担任助理一职。2006年7月，Mr. Van Naarden在Goldman Sachs开始他的职业生涯直至2008年6月。 Mr. Van Naarden获得了Princeton University分子生物学学士学位。
Jacob Van Naarden,served as chief executive officer-Loxo Oncology at Lilly, and chief operating officer-Loxo Oncology at Lilly. Mr. Van Naarden joined Lilly in 2019 when the company acquired Loxo Oncology, Inc., where he was the chief operating officer. In previous roles, Mr. Van Naarden worked in various biotechnology investing, operating, and advisory capacities, including positions with HealthCor Management, Aisling Capital, and Goldman Sachs. Mr. Van Naarden has five years of service with Lilly.- Jacob Van Naarden，自2015年12月起担任Loxo Oncology, Inc.首席商务官，自2014年5月担任Loxo Oncology, Inc.开发战略部副总裁。加入Loxo Oncology前，2013年7月至2014年5月，Mr. Van Naarden曾担任HealthCor Management分析师。2008年8月至2013年6月，Mr. Van Naarden曾在Aisling Capital任职，一开始担任分析师后担任助理一职。2006年7月，Mr. Van Naarden在Goldman Sachs开始他的职业生涯直至2008年6月。 Mr. Van Naarden获得了Princeton University分子生物学学士学位。
- Jacob Van Naarden,served as chief executive officer-Loxo Oncology at Lilly, and chief operating officer-Loxo Oncology at Lilly. Mr. Van Naarden joined Lilly in 2019 when the company acquired Loxo Oncology, Inc., where he was the chief operating officer. In previous roles, Mr. Van Naarden worked in various biotechnology investing, operating, and advisory capacities, including positions with HealthCor Management, Aisling Capital, and Goldman Sachs. Mr. Van Naarden has five years of service with Lilly.
- Johna L. Norton
Johna L. Norton，自2017年4月起担任全球质量高级副总裁。
Johna L. Norton,held various leadership roles with Lilly, including vice president, global quality assurance API manufacturing and product research and development. Ms. Norton has 33 years of service with Lilly.- Johna L. Norton，自2017年4月起担任全球质量高级副总裁。
- Johna L. Norton,held various leadership roles with Lilly, including vice president, global quality assurance API manufacturing and product research and development. Ms. Norton has 33 years of service with Lilly.
- Daniel Skovronsky
Daniel Skovronsky，科学与技术高级副总裁兼礼来研究实验室总裁，于2018年6月生效。2010年加入公司之前，Skovronsky博士是Avid Radiopharmaceutical公司的首席执行官和创始人。
Daniel Skovronsky,Prior to assuming his current role, Dr. Skovronsky served as Executive Vice President, Chief Scientific and Medical Officer, and President, Lilly Research Laboratories since 2018. Dr. Skovronsky has held other leadership roles with Lilly, including as senior vice president, clinical and product development and vice president, diabetes research. Dr. Skovronsky has 13 years of service with Lilly.- Daniel Skovronsky，科学与技术高级副总裁兼礼来研究实验室总裁，于2018年6月生效。2010年加入公司之前，Skovronsky博士是Avid Radiopharmaceutical公司的首席执行官和创始人。
- Daniel Skovronsky,Prior to assuming his current role, Dr. Skovronsky served as Executive Vice President, Chief Scientific and Medical Officer, and President, Lilly Research Laboratories since 2018. Dr. Skovronsky has held other leadership roles with Lilly, including as senior vice president, clinical and product development and vice president, diabetes research. Dr. Skovronsky has 13 years of service with Lilly.
- Anne E. White
Anne E. White自2018年9月起担任礼来肿瘤学高级副总裁兼总裁。
Anne E. White,held various leadership roles with Lilly, including senior vice president and president, Lilly Oncology, vice president of Portfolio Management, Chorus, and Next Generation Research and Development. Ms. White has 28 years of service with Lilly.- Anne E. White自2018年9月起担任礼来肿瘤学高级副总裁兼总裁。
- Anne E. White,held various leadership roles with Lilly, including senior vice president and president, Lilly Oncology, vice president of Portfolio Management, Chorus, and Next Generation Research and Development. Ms. White has 28 years of service with Lilly.
- Donald A. Zakrowski
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Anat Hakim
Anat Hakim，自2020年2月以来担任高级副总裁兼总法律顾问。在加入礼来之前，Hakim女士曾是一家管理型护理公司的执行副总裁，总法律顾问和Wellcare Health Plans秘书。 在加入Wellcare之前，她曾在卫生保健公司Abbott Laboratories担任部门副总裁兼副总法律顾问。
Anat Hakim,was senior vice president, general counsel and secretary of WellCare Health Plans, Inc. (WellCare) from 2016 to 2018, and executive vice president, general counsel and secretary of WellCare from 2018 to 2020. Prior to joining WellCare, she served as divisional vice president and associate general counsel of intellectual property litigation at Abbott Laboratories from 2010 to 2013 and divisional vice president and associate general counsel of litigation from 2013 to 2016. Ms. Hakim has four years of service with Lilly.- Anat Hakim，自2020年2月以来担任高级副总裁兼总法律顾问。在加入礼来之前，Hakim女士曾是一家管理型护理公司的执行副总裁，总法律顾问和Wellcare Health Plans秘书。 在加入Wellcare之前，她曾在卫生保健公司Abbott Laboratories担任部门副总裁兼副总法律顾问。
- Anat Hakim,was senior vice president, general counsel and secretary of WellCare Health Plans, Inc. (WellCare) from 2016 to 2018, and executive vice president, general counsel and secretary of WellCare from 2018 to 2020. Prior to joining WellCare, she served as divisional vice president and associate general counsel of intellectual property litigation at Abbott Laboratories from 2010 to 2013 and divisional vice president and associate general counsel of litigation from 2013 to 2016. Ms. Hakim has four years of service with Lilly.
- Patrik Jonsson
Patrik Jonsson自2019年9月以来，生物医学高级副总裁兼总裁。
Patrik Jonsson,has held various leadership roles with Lilly, including, most recently, as Executive Vice President and President, Lilly Immunology and Lilly USA, and Chief Customer Officer. Previously, he served as senior vice president and president, Lilly Bio-Medicines and president and general manager, Lilly Japan. Mr. Jonsson has 33 years of service with Lilly.- Patrik Jonsson自2019年9月以来，生物医学高级副总裁兼总裁。
- Patrik Jonsson,has held various leadership roles with Lilly, including, most recently, as Executive Vice President and President, Lilly Immunology and Lilly USA, and Chief Customer Officer. Previously, he served as senior vice president and president, Lilly Bio-Medicines and president and general manager, Lilly Japan. Mr. Jonsson has 33 years of service with Lilly.
- Anat Ashkenazi
Anat Ashkenazi，自2021年起担任高级副总裁兼首席财务官。在此之前，Ashkenazi女士在礼来担任过各种领导职务，包括礼来研究实验室的高级副总裁、财务总监和首席财务官，以及Lilly Diabetes和礼来全球制造和质量公司的副总裁、财务总监和首席财务官。Ashkenazi女士在礼来服务了19年。
Anat Ashkenazi,held various leadership roles with Lilly, including senior vice president, controller and chief financial officer, Lilly Research Laboratories, and vice president, finance and chief financial officer, Lilly Diabetes and Lilly global manufacturing and quality. Ms. Ashkenazi has 22 years of service with Lilly.- Anat Ashkenazi，自2021年起担任高级副总裁兼首席财务官。在此之前，Ashkenazi女士在礼来担任过各种领导职务，包括礼来研究实验室的高级副总裁、财务总监和首席财务官，以及Lilly Diabetes和礼来全球制造和质量公司的副总裁、财务总监和首席财务官。Ashkenazi女士在礼来服务了19年。
- Anat Ashkenazi,held various leadership roles with Lilly, including senior vice president, controller and chief financial officer, Lilly Research Laboratories, and vice president, finance and chief financial officer, Lilly Diabetes and Lilly global manufacturing and quality. Ms. Ashkenazi has 22 years of service with Lilly.
- Ilya Yuffa
Ilya Yuffa自2020年起担任礼来生物医药公司高级副总裁兼总裁。此前，Yuffa先生曾在礼来担任过各种领导职务，包括U.S. Diabetes副总裁，意大利中心总经理，以及2014年以来的全球道德和合规官副总裁。Yuffa先生在礼来服务了24年。
Ilya Yuffa,held various leadership roles with Lilly, including senior vice president and president, Lilly Bio-Medicines, vice president of U.S. Diabetes, general manager of Italy Hub, and vice president, global ethics and compliance officer since 2014. Mr. Yuffa has 27 years of service with Lilly.- Ilya Yuffa自2020年起担任礼来生物医药公司高级副总裁兼总裁。此前，Yuffa先生曾在礼来担任过各种领导职务，包括U.S. Diabetes副总裁，意大利中心总经理，以及2014年以来的全球道德和合规官副总裁。Yuffa先生在礼来服务了24年。
- Ilya Yuffa,held various leadership roles with Lilly, including senior vice president and president, Lilly Bio-Medicines, vice president of U.S. Diabetes, general manager of Italy Hub, and vice president, global ethics and compliance officer since 2014. Mr. Yuffa has 27 years of service with Lilly.
- Edgardo Hernandez
Edgardo Hernandez，高级副总裁兼总裁，制造业务自2021。此前，Hernandez曾在礼来担任多个领导职务，包括负责全球肠外药品、递送设备和区域制造的高级副总裁，以及负责费格谢姆运营的副总裁。Hernandez先生在礼来服务了17年。
Edgardo Hernandez,held various leadership roles with Lilly, including senior vice president, global parenteral drug product, delivery devices and regional manufacturing, and vice president, Fegersheim operations. Mr. Hernandez has 19 years of service with Lilly.- Edgardo Hernandez，高级副总裁兼总裁，制造业务自2021。此前，Hernandez曾在礼来担任多个领导职务，包括负责全球肠外药品、递送设备和区域制造的高级副总裁，以及负责费格谢姆运营的副总裁。Hernandez先生在礼来服务了17年。
- Edgardo Hernandez,held various leadership roles with Lilly, including senior vice president, global parenteral drug product, delivery devices and regional manufacturing, and vice president, Fegersheim operations. Mr. Hernandez has 19 years of service with Lilly.
- Diogo Rau
Diogo Rau，高级副总裁兼首席信息和数字军官自2021。在加入礼来之前，Rau先生是苹果公司零售和在线商店信息系统和技术的高级主管，从2011到2021。在苹果任职之前，他曾在麦肯锡公司担任合伙人。
Diogo Rau,was senior director of information systems and technology for retail and online stores of Apple Inc. from 2011 to 2021. Prior to his tenure at Apple, he served as a partner at McKinsey & Company. Mr. Rau has three years of service with Lilly.- Diogo Rau，高级副总裁兼首席信息和数字军官自2021。在加入礼来之前，Rau先生是苹果公司零售和在线商店信息系统和技术的高级主管，从2011到2021。在苹果任职之前，他曾在麦肯锡公司担任合伙人。
- Diogo Rau,was senior director of information systems and technology for retail and online stores of Apple Inc. from 2011 to 2021. Prior to his tenure at Apple, he served as a partner at McKinsey & Company. Mr. Rau has three years of service with Lilly.
- Alonzo Weems
Alonzo Weems，高级副总裁，企业风险管理，以及首席伦理和合规官自2021。此前，Weems曾在礼来担任过各种领导职务，包括公司法律职能副总裁兼副总法律顾问、礼来美国总法律顾问以及生物医学和糖尿病总法律顾问。Weems先生在礼来服务了24年。
Alonzo Weems,held various leadership roles with Lilly, including vice president and deputy general counsel for corporate legal functions, general counsel for Lilly USA, and general counsel for biomedicines and diabetes. Mr. Weems has 26 years of service with Lilly.- Alonzo Weems，高级副总裁，企业风险管理，以及首席伦理和合规官自2021。此前，Weems曾在礼来担任过各种领导职务，包括公司法律职能副总裁兼副总法律顾问、礼来美国总法律顾问以及生物医学和糖尿病总法律顾问。Weems先生在礼来服务了24年。
- Alonzo Weems,held various leadership roles with Lilly, including vice president and deputy general counsel for corporate legal functions, general counsel for Lilly USA, and general counsel for biomedicines and diabetes. Mr. Weems has 26 years of service with Lilly.
- Eric Dozier
Eric Dozier，人力资源和多样性执行副总裁（自2022年起）。此前，他曾担任Lilly的各种领导职务，包括Loxo@Lilly的高级副总裁、首席商务官、副总裁、全球道德和合规官。他在Lilly公司工作了25年。
Eric Dozier,held various leadership roles with Lilly, including senior vice president, chief commercial officer for Loxo@Lilly, and vice president, global ethics and compliance officer. Mr. Dozier has 26 years of service with Lilly.- Eric Dozier，人力资源和多样性执行副总裁（自2022年起）。此前，他曾担任Lilly的各种领导职务，包括Loxo@Lilly的高级副总裁、首席商务官、副总裁、全球道德和合规官。他在Lilly公司工作了25年。
- Eric Dozier,held various leadership roles with Lilly, including senior vice president, chief commercial officer for Loxo@Lilly, and vice president, global ethics and compliance officer. Mr. Dozier has 26 years of service with Lilly.